CMV infection episodes and duration of antiviral therapy are lower in those with more than 10% recipient T-cell chimerism after R+/D− HSCT. The number of CMV reactivations (A) and total number of days of CMV treatment in the R+/D− cohort (B) are shown in relation to recipient chimerism in the T-cell compartment, 10% or less recipient (R) or more than 10% R. A filled circle indicates a patient with CMV disease. The horizontal bar marks the median for the respective cohort. Comparisons between 10% or less R and more than 10% R cohorts were performed using a 2-tailed Mann-Whitney U test.